United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $5.38, $0.23 better than the analyst estimate of $5.15. Revenue for the quarter came in at $609.4 million versus the consensus estimate of $587.9 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.